Year 1 Resolution Update: Coalition Building

**Resolution**
USP will lead and power a stakeholder movement for quality to advance public health and patient safety.

**Alignment with USP’s Mission**
To optimize our impact and increase access to quality medicines globally, USP will activate partners in medicines quality with broad geographic and political reach, including members of the USP Convention. Either as a leader or participant in coalitions, USP can elevate national and global health policy discussions to inform debate around key issues and influence policy outcomes. Engagement of the Convention Membership and coalitions will also position USP and its allies to take on new issues as they arise and create a balanced public narrative. This multifaceted approach will allow USP to provide scientific input on relevant policy issues and deepen its role in the public conversation around medicines safety and quality.

**Year 1 Update**
Key progress areas over the past fiscal year include:

**USP Convention Sectors and Regional Chapters** – The USP Convention launched Sectors and Regional Chapters to connect with Convention Members on shared priorities. Sectors launched are: Biologics, Generic Medicines, Healthcare Practice, and Dietary Supplements. Regional Chapters launched are: South Asia, Latin America, and Greater China. Through these convenings, Convention Members share knowledge, experiences, and perspectives around critical issues impacting quality. They also provide valuable input to USP, informing our work to advance public health and patient safety.

**Call for Collaboration** – The USP-led coalition, “Call for Collaboration,” has advanced shared priorities, including monograph development and modernization to facilitate patient access to medicines. In August 2020, FDA announced support for the coalition’s work to advance expanded access to medicines. The American Cancer Society signed on in September 2020. Targeted outreach to additional patient advocacy and trade groups is continuing.

**Supply Chain Coalitions** – USP continued to collaborate with the American Society of Health-System Pharmacists, American Medical Association, American Hospital Association, American Society of Anesthesiologists, and American Society of Clinical Oncology, to identify advocacy opportunities and policy recommendations to strengthen the healthcare supply chain. Related activities included the July 2020
“Virtual Summit on Safe, Effective, and Accessible High-Quality Medicines as a Matter of National Security.” USP participates in additional supply chain related initiatives, including the: 1) HHS Office of the Assistant Secretary for Preparedness and Response (ASPR); 2) Healthcare and Public Health Sector Coordinating Councils; 3) Federal Emergency Management Agency’s Committee for the Distribution of Medical Resources Necessary to Respond to a Pandemic Plan, Action #2 – Drug Products & Drug Substances; and 4) to-be-developed ASPR Healthcare and Public Health Sector’s Supply Chain Working Group.

**Dietary Supplements Quality Collaborative** – DSQC developed new resources and began stakeholder outreach for consumer protection legislation, gaining coverage in *Morning Consult*, *Nutra-Ingredients USA*, *WholeFoods Magazine*, *Drug Store News*, *Nutritional Outlook*, and *Natural Products Insider*. In September 2020, DSQC hosted a webinar for congressional staffers on ways to advance the quality and safety of dietary supplements.

**Planned for Year 2**

- USP will expand on the foundation established in FY 2020 for increased engagement with Convention Members via Sectors and Regional Chapters, as well as related opportunities for Member dialogue and input, and co-creation of content. We will launch additional Sectors and Chapters, including the Middle East and North Africa Regional Chapter, and the Innovation Sector.

- USP will continue to seek opportunities for coordinated engagement with Convention Members and other stakeholders to identify and prioritize monograph development for greatest impact on public health and patient access, such as working with patient advocacy communities on their needs for products such as complex generics.

- USP will continue to identify opportunities to gain insights and for collaboration in areas where USP and stakeholders can work together to strengthen the resiliency of the medicines supply chain.

- USP will continue to develop spaces for Convention Members and other stakeholders to leverage and amplify collective expertise and networks to help promote safety, advance transparency, and embrace quality in dietary supplements.

**Contact**

For additional information on this Resolution, contact Shelley Whiddon at shelley.whiddon@USP.org.